Navigation Links
Sanofi US and POZEN Sign Exclusive License Agreement for the Commercialization of PA8140/PA32540 Tablets in the U.S.
Date:9/4/2013

cal application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

POZEN Forward-Looking Statements Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on current market data and research (including third party and POZEN sponsored market studies and reports), management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our inability to license our PA product candidates on terms and timing acceptable to us, our inability to file a new drug application with the FDA for our PA product candidates in the timeframe we anticipate, our failure to successfully commercialize our product candidates; costs and delays in the devel
'/>"/>

SOURCE Sanofi US
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Pasteurs Fluzone High-Dose Vaccine Significantly More Effective Than Standard Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older
2. Sanofi Pasteur Announces Shipment of First Lots of 2013-2014 Seasonal Influenza Vaccine in U.S.
3. Sanofi US and Joslin Diabetes Center Announce Results from Multicultural Outreach Pilot at American Diabetes Association Scientific Sessions
4. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
5. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
6. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
7. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
8. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
9. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
10. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
11. NextBio Announces Translational Medicine Partnership with Sanofi
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015 Regen BioPharma, Inc. (OTCBB: RGBP) ... novel means of delivering its patented (US Patent ... tumors utilizing a clinically approved formulation as delivery ... with gene silencing therapeutics in which the gene ... whole body.  By utilizing a local delivery system, ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. , Aug. ... ; EURONEXT: SAN) and the life sciences team at ... care and outcomes for people with type 1 and ... treatments and devices with Google,s expertise in analytics, miniaturized ... explore how to improve diabetes care by developing new ...
(Date:8/31/2015)...  Qualcomm Incorporated (NASDAQ: QCOM ) today ... is collaborating with Davita Healthcare Partners and ... by Qualcomm Life,s 2net™ Device Connectivity Platform and ... informed interventions and better management of at-risk populations. ... Connect 2015 ecosystem conference taking place ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... 7, 2011  Tethys Bioscience has entered into an agreement ... employers measurably flatten the trajectory of their healthcare trends ... their employee populations. The agreement allows ACAP Health to ... as a component of its disease intervention programs. The ...
... 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ... and develops new uses for previously approved drugs and ... of the granting of a European patent with broad ... diketopiperazine which is the active ingredient of Ampion™.  The ...
Cached Medicine Technology:Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 2Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 3Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™ 2
(Date:9/1/2015)... ... September 01, 2015 , ... ... has established the MAP Recovery Network, the Premier Outcomes-Driven Provider Network. It ... rapidly-growing alliance is dedicated to the provision of quality addiction treatment and ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Anthony J. ... the Super Lawyers 2015 for his third consecutive year in a row. Through ... accomplishments of helping people. , Born in Niagara Falls, New York, Tantillo is a ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for the ... understand the scope of their EHS regulatory obligations and rapidly collect, share, archive, ...
(Date:8/31/2015)... West Orange, NJ (PRWEB) , ... September 01, ... ... in the spine to eliminate chronic back pain – once required a long, ... with a shorter hospital stay, less pain, less blood loss and minimal muscle ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... at Western University of Health Sciences to learn more about its integrated approach ... of Dental Sciences and Institute of Cellular Medicine at Newcastle University, and Susan ...
Breaking Medicine News(10 mins):Health News:MAP Health Management Launches the MAP Recovery Network 2Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 2Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 3Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 4Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Western Diabetes Institute Collaborates with UK team 2Health News:Western Diabetes Institute Collaborates with UK team 3Health News:Western Diabetes Institute Collaborates with UK team 4
... (HealthDay News) -- For newly diagnosed cancer patients, appointments with ... those with private health insurance, according to U.S. researchers. ... assistants posing as new cancer patients were unable to obtain ... The findings, from a team at the Perelman School of ...
... data presented at The American Society of Clinical Oncology ... tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has ... to three times more than the current median survival ... Hospitals Case Medical Center, University of California, San Francisco ...
... epidemic, a once-rare form of cancer known as Kaposi,s sarcoma ... was best illustrated by Tom Hanks, who portrayed a gay ... co-workers in the 1993 movie "Philadelphia." A few years ... searching for a postdoctoral position. He found one, in Philadelphia, ...
... , THURSDAY, June 2 (HealthDay News) -- They are ... new research reveals that used faceshields are more likely to ... equipment managers, conducted by Ohio State University, also found that ... replacement policy in place for used or damaged shields. ...
... , THURSDAY, June 2 (HealthDay News) -- Noisy operating rooms ... infections, new study findings suggest. In the report, ... of Surgery , the Swiss researchers also said these surgical ... hospital stays. "SSIs lead to patients spending up to ...
... than 70 with glioblastoma, the most common and aggressive ... for those living in poorer areas and older than ... presented at the American Society of Clinical Oncology annual ... on Saturday, June 4. ( ABSTRACT #6089 ). ...
Cached Medicine News:Health News:U.S. Cancer Patients Face Barriers to Care, Study Finds 2Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 2Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 3Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 4Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 5Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 6Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 7Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 8Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 9Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 10Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 11Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 12Health News:FSU scientist leads research on AIDS-related cancer 2Health News:FSU scientist leads research on AIDS-related cancer 3Health News:Used Football Faceshields May Break on Impact 2Health News:Noisy ORs Linked to Raised Risk of Surgical Site Infection 2Health News:ASCO: Glioblastoma in the 21st century: Wealthier patients living longer than poorer patients 2
Open blade design with aspiration capabilities for removing fluids from the operative site. 19 gauge wire....
Designed to provide open approaches of the keratome to the cornea for either the left or right eye. Lightweight wire design adds to the comfort of the instrument when in place....
Solid 14 mm free-swinging blades, suture posts, and stabilizing disk. Dull finish....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
Medicine Products: